A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.
Saved in:
| Title: | A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy. |
|---|---|
| Authors: | Jang HJ; Department of Epigenetics, Van Andel Institute, Grand Rapids, Michigan., Hostetter G; Pathology and Biorepository Core, Van Andel Institute, Grand Rapids, Michigan., Macfarlane AW; Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Madaj Z; Bioinformatics & Biostatistics Core, Van Andel Institute, Grand Rapids, Michigan., Ross EA; Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Hinoue T; Department of Epigenetics, Van Andel Institute, Grand Rapids, Michigan., Kulchycki JR; Department of Epigenetics, Van Andel Institute, Grand Rapids, Michigan., Burgos RS; Department of Epigenetics, Van Andel Institute, Grand Rapids, Michigan., Tafseer M; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Alpaugh RK; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Schwebel CL; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Kokate R; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Geynisman DM; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Zibelman MR; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Ghatalia P; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Nichols PW; Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California., Chung W; The Coriell Institute for Medical Research, Camden, New Jersey., Madzo J; The Coriell Institute for Medical Research, Camden, New Jersey., Hahn NM; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland., Quinn DI; University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine of USC, Los Angeles, California., Issa JJ; The Coriell Institute for Medical Research, Camden, New Jersey., Topper MJ; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland., Baylin SB; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland., Shen H; Department of Epigenetics, Van Andel Institute, Grand Rapids, Michigan., Campbell KS; Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Jones PA; Department of Epigenetics, Van Andel Institute, Grand Rapids, Michigan., Plimack ER; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. |
| Source: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Jun 01; Vol. 29 (11), pp. 2052-2065. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
